MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
zanubrutinib Sensitive: B - Late Trials
|
zanubrutinib Sensitive: B - Late Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
|
rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
|
MYD88 L265P
|
Lymphoma
|
MYD88 L265P
|
Lymphoma
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
MYD88 L265P
|
Marginal Zone Lymphoma
|
MYD88 L265P
|
Marginal Zone Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
daratumumab Sensitive: C3 – Early Trials
|
daratumumab Sensitive: C3 – Early Trials
|
MYD88 L265P
|
Diffuse Large B Cell Lymphoma
|
MYD88 L265P
|
Diffuse Large B Cell Lymphoma
|
rituximab Resistant: C3 – Early Trials
|
rituximab Resistant: C3 – Early Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
X4P-001 Sensitive: C3 – Early Trials
|
X4P-001 Sensitive: C3 – Early Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
MYD88 L265P
|
NHL
|
MYD88 L265P
|
NHL
|
rituximab Resistant: C3 – Early Trials
|
rituximab Resistant: C3 – Early Trials
|
MYD88 L265P
|
Multiple Myeloma
|
MYD88 L265P
|
Multiple Myeloma
|
lenalidomide + bortezomib Sensitive: C4 – Case Studies
|
lenalidomide + bortezomib Sensitive: C4 – Case Studies
|
MYD88 L265P
|
Diffuse Large B Cell Lymphoma
|
MYD88 L265P
|
Diffuse Large B Cell Lymphoma
|
KT-413 Sensitive: D – Preclinical
|
KT-413 Sensitive: D – Preclinical
|